Home » Newsletters » BioWorld Science

BioWorld Science

May 13, 2009

View Archived Issues

SkinMedica and Allergan sign U.S. copromotion agreement for acne treatment Aczone

Roche partners with Tekmira to advance its RNAi product candidates

Intercell signs supply contract with U.S. military for Japanese encephalitis vaccine Ixiaro

Discovery and FDA to meet in June 2009 regarding marketing approval of Surfaxin

Sanofi-aventis acquires U.S. commercial rights to Antisoma's B-cell CLL drug Oforta

Preclinical data point to activity against psoriasis with PDE7 inhibitor ASB-16165

PAR-2 antagonism with NP-003 possibly useful for atopic dermatitis, skin whitening

Leuprorelin may be beneficial in spinal and bulbar muscular atrophy

Two large studies show antimigraine efficacy of telcagepant

Diabetic peripheral neuropathic pain reduced from severe to mild with tapentadol ER

Aliskiren/amlodipine combination effective in hypertensives treated over one year

Janssen claims gamma-secretase modulators for the treatment of Alzheimer's disease

Janssen describes c-FMS kinase inhibitors for the treatment of inflammatory conditions

Phosphodiesterase 4B inhibitors discovered by Boehringer Ingelheim for respiratory disorders

Topical administration of 17beta-estradiol prodrug confers retinal protection in rat glaucoma model

S1P1 inhibitor XL-541 enhances the oncolytic activity of paclitaxel in preclinical studies

Monoclonal antisera against fibroblast growth factor-2 or its receptor show antineoplastic activity

Dara BioSciences reports favorable results for KRN-5500 in neuropathic pain

FDA accepts Arno's IND for the use of AR-12 in adults with solid tumors or lymphoma

AstraZeneca completes approval procedure for Nexium in preventing peptic ulcer re-bleeding

Pfizer's Lyrica now available for fibromyalgia in Canada

NovImmune reacquires rights to NI-0401 and NI-0501 from Merck Serono

New-generation therapeutic for cognitive impairment enters clinical trials at Synosia

Phase I/II study of lisofylline in type 1 diabetes set to begin

FDA accepts as complete AMAG's resubmission of NDA for Feraheme

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 24, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 24, 2025.
Researchers discover how glioblastoma tumors dodge chemotherapy
BioWorld MedTech
Researchers at the University of Sydney have uncovered a mechanism that may explain why glioblastoma returns after treatment, and the world-first discovery offers...
HIV research is close to a cure but far from ending the pandemic
BioWorld
Advances in antiretroviral therapy (ART) now allow people living with HIV to lead normal lives with undetectable and nontransmissible levels of the virus in their...
ADEL wins $1.04B Sanofi deal for tau-targeting Alzheimer’s drug
BioWorld
ADEL Inc. closed a year-end licensing deal worth up to $1.04 billion with Sanofi SA for ADEL-Y01, a specific tau-targeting Alzheimer’s disease drug candidate in a...